286 related articles for article (PubMed ID: 23357148)
1. How to optimize lipoprotein apheresis treatment--a second look.
Schettler V; Neumann CL; Hagenah GC; Schulz EG; Wieland E
Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
3. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
4. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
[TBL] [Abstract][Full Text] [Related]
5. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
6. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells.
Morawietz H; Goettsch W; Brux M; Reimann M; Bornstein SR; Julius U; Ziemssen T
Atheroscler Suppl; 2013 Jan; 14(1):107-13. PubMed ID: 23357151
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels.
Lamounier-Zepter V; Look C; Ehrhart-Bornstein M; Bornstein SR; Fischer S; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):129-34. PubMed ID: 23357154
[TBL] [Abstract][Full Text] [Related]
9. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
10. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.
Kroon AA; van't Hof MA; Demacker PN; Stalenhoef AF
Atherosclerosis; 2000 Oct; 152(2):519-26. PubMed ID: 10998482
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4.
Moriarty PM; Luyendyk JP; Gibson CA; Backes JM
Am J Cardiol; 2010 Jun; 105(11):1585-7. PubMed ID: 20494666
[TBL] [Abstract][Full Text] [Related]
12. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
Bosch T; Lennertz A; Schenzle D; Dräger J;
J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
[TBL] [Abstract][Full Text] [Related]
13. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
Thiery J; Seidel D
Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
[TBL] [Abstract][Full Text] [Related]
14. One year experience with a low density lipoprotein apheresis system.
Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E
Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
[TBL] [Abstract][Full Text] [Related]
17. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
Tselmin S; Müller G; Schatz U; Julius U; Bornstein SR; Hohenstein B
Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840
[TBL] [Abstract][Full Text] [Related]
19. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
[TBL] [Abstract][Full Text] [Related]
20. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques.
Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Julius U
Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
